A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.
Chemical ID:
MESH:D005934
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Glucagon analog inhibits the reaction [[LEPR gene mutant form results in increased oxidation of Lipids] which results in increased abundance of Thiobarbituric Acid Reactive Substances]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased activity of CAT protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of and results in decreased secretion of ADIPOQ protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of CPT1A mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of PPARA mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased oxidation of and results in decreased metabolism of Fatty Acids]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Cholesterol]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Triglycerides]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Urea]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of ACTA2 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of IL6 protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of INS1 protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of LEP protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of TNF protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of COL1A1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of FASN mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of MMP9 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of SCD1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of SREBF1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of TGFB1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of TNF mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased oxidation of Lipids]; Glucagon analog promotes the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of FGF21 protein]
